More on PSYGF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.02 |
|
|||
| Open | $0.02 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.02 | ||||
| Day Low | $0.02 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 6,114 | ||||
- Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
- Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
- Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
- Psyence Biomedical (PSYG) Approved to List on Nasdaq following Completion of Merger with Newcourt Acquisition Corp
- Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
- Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
- Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
- Psyence Group Announces Resignation of Board Member
- Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
Entities mentioned with PSYGF
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- SPAC | View Related Stories »
- F1 | View Related Stories »
- Maxim Group | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Crude Oil | View Related Stories »
- Show More...
